ASCO’s “rock concert” moments came 17 years apart—in 2005 and 2022

DESTINY-04 results extend HER2-targeted therapy to a larger population in breast cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The plenary session at the ASCO 2022 annual meeting saw that rarest of things at a scientific conference: a standing ovation. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
George W. Sledge Jr., MD
Professor of Medicine, Stanford University School of Medicine
Table of Contents

YOU MAY BE INTERESTED IN

Adapted Argentine tango dance therapy is helping some breast cancer survivors regain natural balance and sensation after experiencing neuropathy, a common side effect of chemotherapy treatment. Expansion of a new clinical study will look further at how this musical movement intervention can “rewire” the brain to improve function after chemotherapy-related nerve changes.
A study published in the journal Immunity reveals a mechanism that allows triple negative breast cancer to develop resistance to therapy. Researchers at Baylor College of Medicine showed that lipid accumulation in tumor cells and nearby immune cells promotes immune suppression, but disrupting lipid formulation reverses treatment resistance and the immunosuppressive microenvironment.
George W. Sledge Jr., MD
Professor of Medicine, Stanford University School of Medicine

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login